Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has approved all agenda items at its 15th Annual General Meeting of Shareholders, including FY2025 financial statements with KRW 4.56T in revenue, the re-election of Inside Director John Chongbo Rim, and the re-election of Jung Yeon Kim as Outside Director while newly appointing her as an Audit Committee Member.
📊 [Key Disclosure Details & Financial Summary]
- Shareholders’ Meeting Overview:
- Meeting Date: 2026-03-20
- Record Date for Voting Rights: 2025-12-31
- Resolutions by Agenda Item:
- Item 1 (Ordinary Resolution): Approval of Financial Statements for the 15th Fiscal Year (2025-01-01 ~ 2025-12-31) — Approved (98.5% in favor)
- Consolidated Performance: Revenue of KRW 4.56T / KRW 4,556,972M, Operating Profit of KRW 2.07T / KRW 2,069,221M, Net Income of KRW 1.78T / KRW 1,784,352M, EPS of KRW 24,091 (Audit Opinion: Unqualified)
- Separate Performance: Revenue of KRW 4.56T / KRW 4,556,972M, Operating Profit of KRW 2.07T / KRW 2,068,093M, Net Income of KRW 1.59T / KRW 1,586,187M, EPS of KRW 23,671 (Audit Opinion: Unqualified)
- Item 2 (Special Resolution): Amendments to the Articles of Incorporation
- Item 2-1 (Exclusion of Cumulative Voting) — Approved (99.7% in favor)
- Item 2-2 (Reflection of Commercial Act Revisions) — Approved (99.9% in favor)
- Item 3 (Ordinary Resolution): Election of Directors
- Item 3-1 (Re-election of Inside Director John Chongbo Rim, 3-year term) — Approved (98.0% in favor)
- Item 3-2 (Re-election of Inside Director Gyun Rho, 3-year term) — Approved (97.6% in favor)
- Item 4 (Ordinary Resolution): Election of Jung Yeon Kim as Outside Director Serving as Audit Committee Member (Re-elected as Outside Director and newly appointed as Audit Committee Member, 3-year term) — Approved (97.8% in favor)
- Item 5 (Ordinary Resolution): Approval of Remuneration Limit for Directors — Approved (90.9% in favor)
- Item 1 (Ordinary Resolution): Approval of Financial Statements for the 15th Fiscal Year (2025-01-01 ~ 2025-12-31) — Approved (98.5% in favor)
- Dividend and Board Structure:
- Dividend: Not Applicable (No cash or stock dividend)
- Board Composition Post-Meeting: 4 Outside Directors out of 7 total Directors (57.14% Outside Directors), 4 Audit Committee Members (All Outside Directors)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Approved Resolutions in the Annual Report
This filing discloses the final voting results of the Annual General Meeting of Shareholders regarding the approval of FY2025 financial statements, director elections, and corporate charter amendments. Confirming that the approved finalized financial statements and executive board composition are reflected accordingly is important for identifying the company’s finalized financial position and governance structure. Details can be verified in the upcoming annual report.
📢 Disclaimer & Source Notice
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Disclaimer: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
